Literature DB >> 29378776

Excess Mortality in Patients With Type 1 Diabetes Without Albuminuria-Separating the Contribution of Early and Late Risks.

Per-Henrik Groop1,2,3,4, Merlin Thomas4, Maija Feodoroff5,2,3, Carol Forsblom5,2,3, Valma Harjutsalo5,2,3,6.   

Abstract

OBJECTIVE: The current study investigated whether the risk of mortality in patients with type 1 diabetes without any signs of albuminuria is different than in the general population and matched control subjects without diabetes. RESEARCH DESIGN AND METHODS: We studied a nationwide, population-based Finnish register of 10,737 patients diagnosed with type 1 diabetes during 1980-2005 and followed for 10 years and 2,544 adults with long-standing diabetes drawn from the Finnish Diabetic Nephropathy Study (FinnDiane). Mortality was compared with the general Finnish population and 6,655 control subjects without diabetes.
RESULTS: The standardized mortality ratio (SMR) was increased during the first 10 years after the diagnosis (2.58 [95% CI 2.07-3.18], P < 0.001). Mortality in adults with long-standing diabetes, but without albuminuria, was no different from that of the general population (1.02 [0.84-1.22], P = 0.83). However, it was higher compared with that of control subjects without diabetes (1.33 [1.06-1.66], P = 0.01). Excess mortality was largely due to acute diabetes complications and ischemic heart disease, which remained more than fourfold higher (mortality rate ratio 4.34 [2.49-7.57]) in adults with type 1 diabetes than in control subjects without diabetes, despite the absence of albuminuria. By contrast, deaths due to alcohol and drugs were reduced in adults with type 1 diabetes (P = 0.007), especially in men.
CONCLUSIONS: Excess mortality in type 1 diabetes is the result of its complications. Acute complications drive an increased SMR in the first years. In individuals who remain free of albuminuria, mortality due to ischemic heart disease is still four times higher, and acute complications also occur.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2018        PMID: 29378776     DOI: 10.2337/dc17-1618

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

Review 1.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

2.  Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status.

Authors:  Erika B Parente; Valma Harjutsalo; Markku Lehto; Carol Forsblom; Niina Sandholm; Per-Henrik Groop
Journal:  Cardiovasc Diabetol       Date:  2020-05-19       Impact factor: 9.951

3.  Effect of kolaviron on islet dynamics in diabetic rats.

Authors:  Omolola R Oyenihi; Marlon E Cerf; Motlalepula G Matsabisa; Nicole L Brooks; Oluwafemi O Oguntibeju
Journal:  Saudi J Biol Sci       Date:  2021-09-06       Impact factor: 4.219

4.  Risk factors, mortality trends and cardiovasuclar diseases in people with Type 1 diabetes and controls: A Swedish observational cohort study.

Authors:  Sara Hallström; Magnus Olof Wijkman; Johnny Ludvigsson; Per Ekman; Marc Alan Pfeffer; Hans Wedel; Annika Rosengren; Marcus Lind
Journal:  Lancet Reg Health Eur       Date:  2022-07-22

Review 5.  The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders.

Authors:  Markku Lehto; Per-Henrik Groop
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-19       Impact factor: 5.555

6.  Waist-height ratio and waist are the best estimators of visceral fat in type 1 diabetes.

Authors:  Erika B Parente; Stefan Mutter; Valma Harjutsalo; Aila J Ahola; Carol Forsblom; Per-Henrik Groop
Journal:  Sci Rep       Date:  2020-10-29       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.